Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

被引:89
|
作者
Prado, JG
Wrin, T
Beauchaine, J
Ruiz, L
Petropoulos, CJ
Frost, SDW
Clotet, B
D'Aquila, RT
Martinez-Picado, J
机构
[1] Univ Autonoma Barcelona, Hosp Germans Trias Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain
[2] Virolog Inc, San Francisco, CA USA
[3] Univ Calif San Diego, Dept Pathol, San Diego, CA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
amprenavir; HIV-1 drug resistance; lopinavir; protease inhibitors; replication capacity; viral fitness;
D O I
10.1097/00002030-200205030-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selective mutations. Methods: HIV-1(IIIB) variants derived from passage in increasing concentrations of amprenavir were studied, as well as 3'Gag/protease recombinants derived from them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 and 84 in the protease as well as a p1/p6 cleavage site mutation at codon 449 in Gag. Their susceptibility (IC50) to various PI and their corresponding replication capacities were evaluated by a single-cycle growth assay and compared with measures using competitive cultures and p24 antigen production. Results: Amprenavir susceptibility decreased with increasing numbers of protease mutations. Changes in lopinavir susceptibility paralleled changes in amprenavir susceptibility. Certain amprenavir-selected mutants conferred greater than 10-fold cross-resistance to lopinavir, including PrL10F/M461/150V-GagL449F (19-fold) and PrL10F/M46I/147V/150V-GagL449F (31-fold). Moreover, one isolate with only two mutations in the protease (L10F/84V) and GagL449F displayed a 7.7-fold increase in lopinavir IC50. Low-level cross-resistance to ritonavir and nelfinavir was also observed. The replication capacity of viruses containing either 184V or 150V was at least 90% lower than the reference virus in the single-cycle assay. The order of relative replication capacity was wild-type > L10F > L10F/184V > L10F/M461/150V > L10F/M461/147V/150V. Conclusion: These results indicate that until more comprehensive genotype-phenotype correlations between amprenavir and lopinavir susceptibility are established, phenotypic testing may be preferable to genotyping to detect cross-resistance, and should be considered when switching patients from a failing amprenavir-containing regimen. This study also provides data on the concordance of replication capacity measurements generated using rapid single-cycle growth and competition assays. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 50 条
  • [31] Replication Capacity of HIV-1 in the Presence of Resistance-Associated Substitutions in Protease Reply
    Grant, Philip
    Coakley, Eoin
    Zolopa, Andrew
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (01) : 166 - 166
  • [32] Multidrug-resistant HIV-1 reverse transcriptase:: Involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors
    Mas, A
    Vázquez-Alvarez, BM
    Domingo, E
    Menéndez-Arias, L
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2002, 323 (02) : 181 - 197
  • [33] Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance
    Su, Chinh Tran-To
    Ling, Wei-Li
    Lua, Wai-Heng
    Haw, Yu-Xuan
    Gan, Samuel Ken-En
    [J]. BMC BIOINFORMATICS, 2016, 17
  • [34] Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance
    Chinh Tran-To Su
    Wei-Li Ling
    Wai-Heng Lua
    Yu-Xuan Haw
    Samuel Ken-En Gan
    [J]. BMC Bioinformatics, 17
  • [35] HIV-1 replication capacity: Setting the pace of disease
    Williamson, Carolyn
    Swanstrom, Ronald
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (12) : 3591 - 3592
  • [36] Interpreting resistance to lopinavir/ritonavir in HIV-1 subtype C patients
    Grossman, Z
    Torten, D
    Shahar, E
    Levy, I
    Risenberg, K
    Chowers, M
    Istomin, V
    Averbuch, D
    Burke, M
    Ram, D
    Maayan, S
    Lorber, M
    Schapiro, JM
    [J]. ANTIVIRAL THERAPY, 2003, 8 (03) : U101 - U101
  • [38] Lopinavir/Ritonavir Resistance in Patients Infected With HIV-1: Two Divergent Resistance Pathways?
    Champenois, Karen
    Baras, Agathe
    Choisy, Philippe
    Ajana, Faiza
    Melliez, Hughes
    Bocket, Laurence
    Yazdanpanah, Yazdan
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (10) : 1677 - 1681
  • [39] KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE
    GULNIK, SV
    SUVOROV, LI
    LIU, BS
    YU, B
    ANDERSON, B
    MITSUYA, H
    ERICKSON, JW
    [J]. BIOCHEMISTRY, 1995, 34 (29) : 9282 - 9287
  • [40] Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP)
    Gonzalez, Emmanuel
    Ballana, Ester
    Clotet, Bonaventura
    Este, Jose A.
    [J]. AIDS, 2011, 25 (13) : 1575 - 1583